BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 31178482)

  • 41. Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis.
    Sato S; Uejima Y; Nanbu M; Suganuma E; Takano T; Tanaka R; Kabuki T; Oguma E; Oh-Ishi T; Kawano Y
    Mod Rheumatol; 2017 Jul; 27(4):652-656. PubMed ID: 27588444
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.
    Xu Y; Yang CS; Li YJ; Liu XD; Wang JN; Zhao Q; Xiao WG; Yang PT
    Clin Rheumatol; 2016 Jan; 35(1):113-6. PubMed ID: 26660480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-MDA5 positive dermatomyositis complicated with rapidly progressive interstitial lung disease - a case report.
    De Backer E; Gremonprez F; Brusselle G; Depuydt P; Van Dorpe J; Van Haverbeke C; Goeminne PC; Derom E
    Acta Clin Belg; 2018 Dec; 73(6):413-417. PubMed ID: 29287518
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
    Suzuki A; Kondoh Y; Taniguchi H; Tabata K; Kimura T; Kataoka K; Ono K; Hashisako M; Fukuoka J
    Respir Med Case Rep; 2016; 19():5-8. PubMed ID: 27354955
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness and safety of plasma exchange for anti-MDA5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series.
    Watanabe T; Taniguchi M; Ogura S; Asou M; Takayanagi S; Sokai Y; Tsuji Y; Mori KP; Endo T; Nakajima T; Imura Y; Tsukamoto T
    Ther Apher Dial; 2024 Jun; 28(3):432-441. PubMed ID: 38225794
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies.
    Sato S; Murakami A; Kuwajima A; Takehara K; Mimori T; Kawakami A; Mishima M; Suda T; Seishima M; Fujimoto M; Kuwana M
    PLoS One; 2016; 11(4):e0154285. PubMed ID: 27115353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis.
    Gui X; Ma M; Ding J; Shi S; Xin X; Qiu X; Zhang Y; Qiu Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
    Rheumatology (Oxford); 2021 Aug; 60(8):3913-3922. PubMed ID: 33501503
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
    Yashiro M; Asano T; Sato S; Kobayashi H; Watanabe H; Miyata M; Migita K
    Fukushima J Med Sci; 2018; 64(2):89-94. PubMed ID: 30158335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.
    Peng Y; Zhang S; Zhao Y; Liu Y; Yan B
    Clin Rheumatol; 2018 Jan; 37(1):107-115. PubMed ID: 28842784
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
    Hama S; Akiyama M; Higashida-Konishi M; Oshige T; Takei H; Izumi K; Oshima H; Okano Y
    Mod Rheumatol Case Rep; 2023 Jan; 7(1):92-95. PubMed ID: 35680682
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.
    Qiu Y; Feng X; Liu C; Shi Y; Xu L; You H; Wang L; Lv C; Wang F; Tan W
    Arthritis Res Ther; 2024 Jan; 26(1):9. PubMed ID: 38167532
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
    Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
    Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lung transplantation for anti-MDA5-positive dermatomyositis-associated rapid progressive interstitial lung disease: report of two cases and review of the literature.
    Lian QY; Chen A; Zhang JH; Xu X; Huang DX; Luo Q; He JX; Ju CR
    Clin Rheumatol; 2023 Mar; 42(3):941-947. PubMed ID: 36441397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.
    He C; Li W; Xie Q; Yin G
    Front Immunol; 2021; 12():820163. PubMed ID: 35116041
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.
    Wu W; Guo L; Fu Y; Wang K; Zhang D; Xu W; Chen Z; Ye S
    Clin Rev Allergy Immunol; 2021 Apr; 60(2):293-304. PubMed ID: 33405101
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.
    Gono T; Kawaguchi Y; Satoh T; Kuwana M; Katsumata Y; Takagi K; Masuda I; Tochimoto A; Baba S; Okamoto Y; Ota Y; Yamanaka H
    Rheumatology (Oxford); 2010 Sep; 49(9):1713-9. PubMed ID: 20498012
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An Atypical Clinical Course of Anti-MDA5 Antibody-positive Interstitial Lung Disease in a Patient with Three Deteriorations in 9 years.
    Sato Y; Otsuka K; Tamai K; Ono Y; Hamaguchi Y; Tomii K
    Intern Med; 2017; 56(3):341-346. PubMed ID: 28154280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.
    Kawasumi H; Katsumata Y; Nishino A; Hirahara S; Kawaguchi Y; Kuwana M; Yamanaka H
    J Rheumatol; 2018 Jul; 45(7):947-955. PubMed ID: 29657141
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level.
    Osawa T; Morimoto K; Sasaki Y; Matsuda S; Yamana K; Yano R; Uchiyama T; Goto H
    Intern Med; 2018 Feb; 57(3):387-391. PubMed ID: 29093381
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
    Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
    Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.